Hormone Research in Paediatrics
Workshop: Compliance in GH Treatment
The Clinical Usefulness of Liquid Human Growth Hormone (hGH) (Norditropin® SimpleXxTM) in the Treatment of GH DeficiencyIyoda K.a · Moriwake T.b · Seino Y.b · Niimi H.cDepartments of Pediatrics, aNippon Kokan Fukuyama Hospital, Fukuyama, Hiroshima, bOkayama University Medical School, Okayama, cChiba University, School of Medicine, Chiba, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: November 17, 2004
Issue release date: November 1999
Number of Print Pages: 3
Number of Figures: 2
Number of Tables: 3
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Abstract
Human growth hormone (hGH) is an essential therapeutic drug for the treatment of GH deficiency. The development of recombinant GH using a pen injection system has enabled easy and safe treatment of GH-deficient patients; however, the process of dissolving hGH in the powder form is complicated and dangerous. In this study, we investigated the usefulness of a newly developed liquid form of hGH (Norditropin® SimpleXxTM) in the treatment of 51 patients with GH deficiency. Fifteen previously untreated patients with GH deficiency were treated with liquid hGH (group A), and 36 patients who had previously used hGH in the powder form were changed to the liquid form (group B). Both groups were treated with liquid hGH 0.5 IU/kg per week for 6 months. The growth rate of patients in group A increased from 4.0 ± 2.4 cm/year to 9.2 ± 2.9 cm/year. The patients in group B continued to grow at the same rate as before using the liquid hGH therapy. Questionnaires to the patients in group B demonstrated that 85% preferred the convenience of using the new liquid form of hGH. Our results indicate that liquid hGH has similar efficacy to that of powder hGH, but its improved convenience may have a beneficial effect on patient compliance.
© 1999 S. Karger AG, Basel
Related Articles:
References
- Rosenbloom AL, Knuth C, Shulman D: Growth hormone by daily injection in patients previously treated for growth hormone deficiency. South Med J 1990;83:653–655.
- Jorgensen JT: Improvement of patient convenience in treatment with growth hormone. J Pediatr Endocrinol 1994;7:175–180.
-
Suwa S, Tachibana K, Maesaka H, Tanaka T, Yokoya S: Longitudinal standards for height and height velocity for Japanese children from birth to maturity. Clin Pediatr Endocrinol 1992;1:5–13.
-
Oyarzabal M, Aliaga M, Chueca M, Echarte G, Ulied A: Multicentre survey o compliance with growth hormone therapy: what can be improved? Acta Pædiatr 1998;87:387–391.
Article / Publication Details
Published online: November 17, 2004
Issue release date: November 1999
Number of Print Pages: 3
Number of Figures: 2
Number of Tables: 3
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
